Skip to main content
Premium Trial:

Request an Annual Quote

Marlboro’s Genome Man


“I’m not averse to having a cigarette or cigar now and then,” says North Carolina State University’s Charles Opperman — not exactly a glowing endorsement for someone who just received $17.6 million from Philip Morris. But that’s not why he’s heading up the Tobacco Genome Initiative, funded by the cigarette maker. “I work with tobacco because it’s a good host for nematodes,” Opperman says.

The parasitic worm expert will spend the next four-and-a-half years tackling the Hicks variety of tobacco, a strain highly susceptible to several diseases. “We’re not going to sequence the entire genome,” says Opperman, 45. “It’s one-and-a-half times the size of the human.” Instead, his lab will map the entire genome, and then “try to sequence as many genes as we can.”

A native of New York City, “I had no agricultural background,” Opperman says. “I’d been on a horse a few times, but I don’t think that really counts, does it?” He discovered a soft spot for protecting crops from nematode freeloaders as a student at the University of Florida.

“It was purely an accident,” he says. “I was working in a cancer lab as an undergraduate and I needed a summer course to keep my job, and the only one I could get into was introduction to plant nematology,” he says. “I liked agriculture so much I immediately switched my degree to agronomy.” He went on to earn a PhD in nematology in 1985 with minors in plant breeding and plant pathology, followed by a two-year stint at Union Carbide Agricultural Products, before joining NCSU’s department of plant pathology.

“Hell, these things happen,” he says. “You can’t always predict where you end up.”

— Aaron J. Sender


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.